Neuroectodermal Tumors, Primitive
7
2
2
2
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
28.6%
2 terminated out of 7 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors
NAC to Prevent Cisplatin-induced Hearing Loss
Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood